Immune response to SARS-CoV-2 vaccination in relation to peripheral immune cell profiles among patients with multiple sclerosis receiving ocrelizumabSaskia Räuber, David Kremer, Karin von Wnuck Lipinski et al.|Journal of Neurology Neurosurgery & Psychiatry|2022Cited by 30
Effect of Previous Disease-Modifying Therapy on Treatment Effectiveness for Patients Treated With OcrelizumabSteffen Pfeuffer, Sven G. Meuth, Leoni Rolfes et al.|Neurology Neuroimmunology & Neuroinflammation|2023Cited by 10
Flow cytometry identifies changes in peripheral and intrathecal lymphocyte patterns in CNS autoimmune disorders and primary CNS malignanciesSaskia Räuber, Nico Melzer, Andreas Schulte‐Mecklenbeck et al.|Journal of Neuroinflammation|2024Cited by 10
Vaccine-based clinical protection against SARS-CoV-2 infection and the humoral immune response: A 1-year follow-up study of patients with multiple sclerosis receiving ocrelizumabSaskia Räuber, David Kremer, Alice Willison et al.|Frontiers in Immunology|2022Cited by 9